Drugs / Glucose
Glucose
Trials 34
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05603364 | Nov 2022 → Jun 2023 | — | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT02866435 | Nov 2016 → Sep 2019 | hypoglycemia | University of Minnesota | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03905408 | Sep 2019 → Feb 2021 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 1 | NCT00823108 | Mar 2009 → Oct 2010 | infectious disease with sepsis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00213551 | Apr 2004 → Jun 2008 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05627479 | Dec 2024 → Jan 2026 | bone disorder | NYU Langone Health | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06469970 | Nov 2024 → Mar 2027 expected | — | Centre Hospitalier Régional Metz-Thionville | Recruiting | No outcome recorded |
| Phase 2 | NCT04129190 | Oct 2019 → Jan 2020 | gestational diabetes | Isra University | Unknown | No outcome recorded |
| Phase 2 | NCT04001036 | Sep 2019 → Aug 2022 | end stage renal failure | Iperboreal Pharma Srl | Terminated | No outcome recorded |
| Phase 2 | NCT01242904 | Sep 2010 → Feb 2015 | end stage renal failure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT00858182 | May 2009 → Oct 2012 | end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00426114 | — | — | University Hospital, Ghent | Withdrawn | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02374281 | Dec 2014 → Apr 2015 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 3 | NCT02325583 | Jan → Oct 2014 | epilepsy, hydrocephalus | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00062972 | Sep 1999 → Aug 2002 | multiple sclerosis | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT04106882 | Jun 2015 → Sep 2022 | — | Stony Brook University | Unknown | No outcome recorded |
| Phase 4 | NCT04840095 | Jun 2015 → Sep 2023 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01384656 | Feb 2011 → Feb 2012 | acute coronary syndrome | Yonsei University | Completed | Met primary |
| Phase 4 | NCT00278057 | May 2003 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07830537 | Oct 2026 → Nov 2027 expected | type 2 diabetes mellitus | The Affiliated Hospital of Qingdao University | Not yet recruiting | No outcome recorded |
| — | NCT06955130 | Jul 2026 → Apr 2029 expected | obesity disorder, type 2 diabetes mellitus | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| — | NCT06155825 | Dec 2023 → Dec 2024 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT07014735 | Apr 2023 → May 2026 | hyperglycemia, torsades de pointes, type 2 diabetes mellitus | Richmond Pharmacology Limited | Terminated | No outcome recorded |
| — | NCT03690232 | Oct 2018 → Jun 2020 | osteoarthritis, knee | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT03486015 | Mar 2016 → Apr 2017 | — | Region Örebro County | Completed | No outcome recorded |
| — | NCT02411318 | Sep 2014 → Dec 2019 | defective phagocytic cell chemotaxis | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT01919788 | Aug 2013 → Apr 2014 | hypoglycemia, type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT01931020 | Jul 2013 → Jul 2014 | — | Lady Hardinge Medical College | Completed | No outcome recorded |
| — | NCT01514253 | Feb → May 2012 | — | The Baruch Padeh Medical Center, Poriya | Unknown | No outcome recorded |
| — | NCT01289808 | Feb → May 2011 | perinatal disease | The Baruch Padeh Medical Center, Poriya | Terminated | No outcome recorded |
| — | NCT01308359 | Jan 2011 → Jan 2012 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00788242 | Jan 2009 → Dec 2013 | aortic valve stenosis, coronary artery disorder, heart failure | Christoph Ellenberger | Completed | No outcome recorded |
| — | NCT00005889 | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| — | NCT00004451 | Mar 1998 → ? | Parkinson disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Comparator or background therapy51 trials | ||||||
| Phase 1 | NCT05737927 Comparator | Sep → Nov 2020 | obesity disorder | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Phase 1 | NCT04409665 Comparator | Jan 2020 → Mar 2022 | newborn respiratory distress syndrome | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 1 | NCT05713773 Comparator | Oct → Dec 2019 | metabolic syndrome X, obesity disorder | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Phase 1 | NCT03315338 Background | Sep 2017 → Feb 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01300260 Background | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 1/2 | NCT00800085 Comparator | Oct 2006 → Oct 2014 | type 1 diabetes mellitus | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 2 | NCT03337477 Comparator | Feb → Dec 2018 | — | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT02180412 Background | Apr 2014 → Feb 2022 | porphyria | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 2 | NCT02607839 Comparator | Feb 2013 → Apr 2015 | — | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01516138 Comparator | Feb 2012 → Mar 2013 | — | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00755456 Comparator | Jan 2008 → Sep 2012 | end stage renal failure | Iperboreal Pharma Srl | Completed | Missed primary |
| Phase 2 | NCT00755404 Comparator | Jun 2007 → Oct 2013 | diabetes mellitus, end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00282867 Comparator | May 2006 → Feb 2008 | hyperglycemia, ischemic stroke | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00814008 Background | Mar 1999 → Apr 2000 | retinal disorder, type 1 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/3 | NCT03860688 Background | May 2019 → Dec 2021 | hyperlipidemia | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT03883763 Background | Apr 2022 → Apr 2023 | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT05962255 Comparator | Feb 2022 → Apr 2024 | heart failure | Wroclaw Medical University | Completed | Met primary |
| Phase 3 | NCT00965406 Background | Aug 2010 → Dec 2013 | acute coronary syndrome | University of Monastir | Completed | Met primary |
| Phase 4 | NCT07189091 Comparator | Oct 2025 → Apr 2028 expected | — | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 4 | NCT06624956 Comparator | Sep 2024 → Sep 2025 | hyperglycemia | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT06739473 Background | Jan 2023 → Dec 2024 overdue | obesity disorder | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05496764 Comparator | Dec 2021 → Jan 2023 | carpal tunnel syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03666546 Comparator | Nov 2018 → Mar 2019 | type 2 diabetes mellitus | Fresenius Kabi | Completed | No outcome recorded |
| Phase 4 | NCT03126084 Comparator | May → Nov 2017 | — | Bozyaka Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02657252 Comparator | Jan 2015 → Sep 2016 | telangiectasis, varicose disease | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
| Phase 4 | NCT02054325 Comparator | Sep 2012 → Dec 2014 | varicose disease | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
| Phase 4 | NCT01387477 Comparator | Jun 2011 → Jun 2012 | hypoglycemia | Institut d'Anesthesiologie des Alpes Maritimes | Withdrawn | No outcome recorded |
| Phase 4 | NCT01253889 Comparator | Dec 2010 → Jun 2013 | — | Children's & Women's Health Centre of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01209403 Comparator | Sep 2010 → Jul 2011 | end stage renal failure | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00709839 Background | Jun → Oct 2008 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00558155 Background | Jun 2001 → Dec 2005 | gastric cancer, malignant pancreatic neoplasm | Jagiellonian University | Completed | Missed primary |
| — | NCT07114263 Background | Aug 2025 → Feb 2026 overdue | — | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT06061783 Comparator | Nov 2023 → Sep 2024 | — | Hospital Civil de Guadalajara | Unknown | No outcome recorded |
| — | NCT05874804 Comparator | Sep 2023 → Oct 2025 | end stage renal failure | Triomed AB | Completed | No outcome recorded |
| — | NCT04967118 Comparator | May 2023 → May 2024 | — | University of Oulu | Unknown | No outcome recorded |
| — | NCT05589441 Background | Oct 2022 → Oct 2023 | — | First Affiliated Hospital Xi'an Jiaotong University | Unknown | Met primary |
| — | NCT05464966 Background | Jun 2022 → May 2023 | — | Yangzhou University | Completed | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
| — | NCT03273881 Comparator | Oct 2017 → Dec 2023 | diabetes mellitus, obstetric disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| — | NCT02622854 Comparator | Jun 2016 → Aug 2020 | acute pancreatitis | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02166359 Comparator | Jun 2014 → Mar 2019 | end stage renal failure | Dong-A University | Completed | No outcome recorded |
| — | NCT02036372 Comparator | Jan 2014 → Jan 2017 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT01706341 Comparator | Oct 2012 → Oct 2013 | — | Nagoya City University | Unknown | No outcome recorded |
| — | NCT01402037 Background | Jul 2011 → Jul 2015 | type 1 diabetes mellitus | University Hospital Brussels | Unknown | No outcome recorded |
| — | NCT01170858 Comparator | Aug 2010 → Aug 2014 | end stage renal failure | Yonsei University | Completed | No outcome recorded |
| — | NCT02305069 Background | Oct 2009 → Oct 2011 | muscular atrophy, obesity disorder | University of Nottingham | Completed | No outcome recorded |
| — | NCT00899483 Comparator | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | University Hospital Birmingham | Unknown | No outcome recorded |
| — | NCT01213563 Comparator | Jan 2009 → Sep 2010 | type 2 diabetes mellitus | Imperial College London | Terminated | No outcome recorded |
| — | NCT00761059 Comparator | Oct 2008 → Dec 2009 | — | University of Cologne | Unknown | No outcome recorded |
| — | NCT01225159 Background | Sep 2008 → Mar 2009 | hypoglycemia, nosocomial infection | Prince of Songkla University | Terminated | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Abbott | Regulatory Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes mediaroom.com ↗
Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. |
| 2026-05-27 | Abbott | Regulatory Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes mediaroom.com ↗
Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes. |
| 2025-12-30 | Lexaria Bioscience Corp. | Results Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 lexariabioscience.com ↗ |
| 2025-11-06 | Prokidney | Results ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 prokidney.com ↗
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with advanced CKD and diabetes. |
| 2025-07-08 | Prokidney | Results ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes prokidney.com ↗
In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). |
| 2025-06-23 | Corcept Therapeutics | Results Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care corcept.com ↗
Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c (HbA1c), which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo (p-value: < 0.001). |
| 2024-08-21 | Lexaria Bioscience Corp. | Results Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the “Study”). |
| 2024-05-25 | AstraZeneca | Results Early chronic kidney disease intervention could save four European health systems up to €15.8 billion over 10 years astrazeneca.com ↗
A preliminary analysis shows that during a 12-month follow-up period, patients taking renin-angiotensin-system inhibitors and sodium-glucose co-transporter-2 inhibitors had a 67% lower risk of all-cause mortality (HR 0.33; 95% CI: 0.12-0.80; p=0.019) and a 20% lower risk of all-cause hospitalisation (HR 0.80; 95% CI: 0.64-0.99; p=0.042) compared to patients not receiving kidney-protective medication. |
| 2018-05-10 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "DOXOFYLLINE GLUCOSE FOR INJECTION" AND "DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION" irasia.com ↗
The board of directors (the “ Board”) of the CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “ Group”) is pleased to announce that the “Doxofylline Glucose for Injection” and “Doxofylline Sodium Chloride for Injection” developed by the Group have been granted drug registration approval by the China Food and Drug Administration of the People’s Republic of China. |
| 2009-03-31 | Eli Lilly and Company | Results Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study lilly.com ↗
There was no major hypoglycemia in any treatment group. |
All press releases naming this drug 44 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucose | “A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused” NCT01225159 ↗84“Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients.” NCT00858182 ↗ “Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.” NCT05589441 ↗ “Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.” NCT05627479 ↗ “glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).” NCT01516138 ↗ “it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily.” NCT06061783 ↗ “Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland)” NCT00558155 ↗ “200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks” NCT01242904 ↗ “Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A).” NCT01213563 ↗ “GIK solution (potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)” PMID 22986417 ↗ Sep 2012 “PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges” NCT00755404 ↗ |
| Known as | Glucose Monohydrate | “Glucose Monohydrate” NCT03666546 ↗ |
| Known as | Glucose PROAMP 30%, Laboratoires AGUETTANT | “Glucose PROAMP 30%, Laboratoires AGUETTANT” NCT02374281 ↗ |
| Route | Intravenous | “[U-13C]glucose IV beginning at zero hour” NCT00005889 ↗ |